To address this situation, the development of new anticancer drugs that target specific molecular pathways activated in cancers, such as epidermal growth factor receptor (EGFR) signaling, has brought excitement in lung cancer studies in the middle of the last decade2. This evidence concerns the gene EGFR and cancer.